Abstract
Semaglutide has been widely used in the treatment of type 2 diabetes (T2D) and obesity within medical and healthcare settings. Among its formulations, Ozempic has drawn attention for potential adverse effects (AEs). In a study involving 3,962 cases of obesity, the average data showed a weight reduction of 11.8%, a BMI decrease of 4.5 kg/m², and a reduction in waist circumference of 9.4 cm. One notable effect, termed “Ozempic tongue,” is characterized by altered taste sensitivity—such as sour, metallic, or bitter tastes—reported in approximately 6% of cases. These effects are not only considered AEs but are also linked to beneficial outcomes in weight reduction. Additionally, some users have reported changes in the appearance of the breasts, buttocks, and lips with Ozempic administration.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call